Fellow
Siri Choragudi
University of Miami Miller School of Medicine
Mentor
Gil Yosipovitch, MD
University of Miami Miller School of Medicine
Overview
A common and often unbearable side effect of cholestatic genetic liver disease is that patients experience uncontrollable itch due to increased levels of bile acids in the bloodstream. This side effect is especially difficult for children to deal with, as they may have limited understanding of their conditions and little experience coping with significant physical discomfort. IBAT inhibitors, drugs that can reduce bile acids and therefore itchiness, were recently approved by the FDA for use in children. However, little is known about the efficacy of these drugs in this population. This research study aims to fill this gap in knowledge and improve treatment by using an in-depth Itch Severity, Quality of Life and Well Being surveys to assess 30-40 pediatric liver transplant patients’ experiences before and after IBAT inhibitor use.
Status
This project was funded through a 2022 PeDRA Research Fellowship Grant.
